Altheos was a biopharmaceutical company focused on the development of small molecule drugs.
Business Model:
Revenue: $0
Employees: 11-50
Address:
City: South San Francisco
State: California
Zip:
Country: United States
Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 2/2012 | Series A | 3 | $12.5M |
Bay City Capital Canaan Partners Novo Holdings Bay City Capital Canaan Partners Novo Holdings |
4/2010 | Series A | 5 | $20M |
Atheneos Ventures Bay City Capital Canaan Partners Life Science Angels Novo Holdings Atheneos Ventures Bay City Capital Canaan Partners Life Science Angels Novo Holdings |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|